Medical School · Year 2 · Gastrointestinal · includes a discussion video

Lecture 15: Nutrition and Malabsorption

Unit 2.2: Gastrointestinal System

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe nutritional assessment and macronutrient requirements
2. Explain the pathophysiology of malabsorption syndromes
3. Describe specific nutrient deficiencies and their clinical manifestations
4. Explain enteral and parenteral nutrition principles
5. Describe obesity and metabolic consequences
6. Explain refeeding syndrome and its prevention

Lecture Outline

I. Nutritional Assessment

Nutritional assessment provides a comprehensive evaluation of a patient's nutritional status, integrating multiple data sources to identify malnutrition and guide intervention. No single measure suffices; rather, the combination of history, examination, anthropometrics, laboratory markers, and functional assessment creates a complete picture.

The history explores dietary patterns through 24-hour recalls or food frequency questionnaires, recent weight changes (unintentional loss is particularly concerning), appetite fluctuations, and symptoms suggesting malabsorption such as diarrhea or steatorrhea. Social factors including food access, economic constraints, and living situation significantly influence nutritional status.

Physical examination reveals stigmata of malnutrition: temporal wasting indicates loss of fat stores, while decreased muscle bulk in the interosseous spaces, thenar eminence, or quadriceps suggests protein depletion. Peripheral edema may indicate hypoalbuminemia. Skin changes include poor wound healing, dermatitis, and easy bruising. Hair becomes thin, dry, and easily pluckable (flag sign in kwashiorkor). Cheilosis (angular stomatitis) and glossitis suggest B-vitamin deficiencies.

Anthropometric measurements provide objective data. Weight should be compared to usual body weight and ideal body weight. Body Mass Index (BMI), calculated as weight in kilograms divided by height in meters squared, classifies nutritional status: underweight (below 18.5), normal (18.5-24.9), overweight (25-29.9), Class I obesity (30-34.9), Class II obesity (35-39.9), and Class III or morbid obesity (40 or above). Waist circumference indicates visceral adiposity; greater than 102 cm in men or 88 cm in women confers metabolic risk.

The ASPEN/AND consensus criteria diagnose malnutrition when two or more of the following are present: insufficient energy intake, weight loss, loss of muscle mass, loss of subcutaneous fat, localized or generalized fluid accumulation masking weight loss, or diminished functional status measured by grip strength.

Laboratory markers include proteins synthesized by the liver, though all are negative acute phase reactants (decreasing with inflammation regardless of nutritional status). Albumin has a 20-day half-life, reflecting long-term status but falling acutely with inflammation, surgery, or liver disease. Prealbumin (transthyretin) has a 2-3 day half-life, responding more quickly to nutritional changes and refeeding. Transferrin's 8-day half-life provides intermediate assessment. Retinol-binding protein's 12-hour half-life offers the most rapid response but limited clinical utility.

Functional assessment through grip strength dynamometry correlates with muscle mass and predicts surgical outcomes. Gait speed and six-minute walk distance assess functional capacity.

<image>Panel A: BMI classification gradient bar from underweight (below 18.5) through normal (18.5-24.9), overweight (25-29.9), and obesity classes I-III (30-40+). Panel B: Physical examination findings of malnutrition including temporal wasting, interosseous muscle wasting, peripheral pitting edema, cheilosis, and koilonychia. Panel C: Serum protein half-life comparison graph showing albumin (20 days), prealbumin (2-3 days), transferrin (8 days), and retinol-binding protein (12 hours). Panel D: ASPEN/AND consensus criteria for malnutrition diagnosis with notation that all hepatic protein markers decrease with inflammation regardless of nutritional status.</image>

II. Macronutrient Requirements

Understanding macronutrient requirements enables appropriate nutritional prescriptions tailored to patient condition and metabolic demands. Energy, protein, carbohydrate, and fat each serve distinct physiological roles.

Energy requirements vary based on basal metabolic rate, activity, and illness severity. Basal metabolic rate approximates 25 kcal/kg/day in healthy adults. Activity factors multiply this baseline: sedentary patients require 1.2 times BMR, moderately active patients 1.3-1.4 times, and highly active individuals up to 1.5 times. Illness introduces stress factors: mild stress (1.1-1.2), moderate stress such as infection (1.2-1.4), and severe stress such as major burns or trauma (1.4-1.5). The typical hospitalized patient requires 25-35 kcal/kg/day.

Estimation equations include the Harris-Benedict equation (incorporating gender, weight, height, and age) and the Mifflin-St Jeor equation, which may be more accurate in obese patients. Indirect calorimetry measures oxygen consumption and carbon dioxide production to calculate actual energy expenditure, representing the gold standard but requiring specialized equipment.

Carbohydrates should comprise 45-65% of total calories. The brain requires approximately 130 grams daily of glucose under normal circumstances (this decreases during prolonged fasting as ketone utilization increases). Fiber intake of 25-35 grams daily promotes colonic health, improves glycemic control, and reduces cardiovascular risk. Complex carbohydrates from whole grains, fruits, and vegetables provide sustained energy release compared to refined sugars.

Protein requirements vary substantially by clinical context. The Recommended Dietary Allowance for healthy adults is 0.8 g/kg/day. Critical illness dramatically increases protein needs to 1.2-2.0 g/kg/day to support wound healing, immune function, and prevent catabolism of lean body mass. Chronic kidney disease without dialysis requires restriction to 0.6-0.8 g/kg/day to reduce uremic toxin production, while dialysis patients need 1.2 g/kg/day to compensate for protein losses during treatment. Hepatic encephalopathy traditionally prompted protein restriction, though current practice favors adequate protein with branched-chain amino acids. Nine essential amino acids cannot be synthesized and must be obtained from diet; complete proteins from animal sources contain all essential amino acids.

Fat should constitute 20-35% of calories, providing essential fatty acids, enabling absorption of fat-soluble vitamins (A, D, E, K), and serving as precursors for hormones and cell membranes. Linoleic acid (omega-6) and alpha-linolenic acid (omega-3) are essential fatty acids that cannot be synthesized de novo. Essential fatty acid deficiency, which can develop within weeks in patients receiving fat-free parenteral nutrition, manifests as scaly dermatitis, alopecia, impaired wound healing, and thrombocytopenia.

<image>Panel A: Energy calculation flowchart showing BMR (25 kcal/kg) multiplied by activity factor (1.2-1.5) and stress factor (1.1-1.5) with typical hospitalized patient requirement of 25-35 kcal/kg/day. Panel B: Protein requirements bar chart comparing healthy adult (0.8 g/kg), dialysis (1.2 g/kg), critical illness (1.2-2.0 g/kg), and CKD non-dialysis (0.6-0.8 g/kg). Panel C: Essential fatty acids pathway from dietary linoleic acid (omega-6) and alpha-linolenic acid (omega-3) to arachidonic acid and EPA/DHA with roles in inflammation, membranes, and hormones. Panel D: Carbohydrate requirements showing 45-65% of total calories, brain glucose requirement of 130 g/day, and fiber intake of 25-35 g/day.</image>

III. Malabsorption - Overview

Malabsorption syndromes result from impaired nutrient absorption at one or more phases of the digestive process, leading to deficiency states despite adequate intake. Understanding the three phases of absorption helps localize dysfunction and guide diagnostic evaluation.

Luminal phase disorders impair initial digestion within the intestinal lumen. Pancreatic exocrine insufficiency reduces lipase, amylase, and protease secretion necessary for macronutrient breakdown. Bile acid deficiency from cholestatic liver disease or ileal resection prevents micelle formation required for fat absorption. Small intestinal bacterial overgrowth (SIBO) causes premature deconjugation of bile acids and consumption of nutrients by bacteria.

Mucosal phase disorders damage the absorptive surface of the small intestine. Celiac disease causes villous atrophy through gluten-triggered autoimmune inflammation. Crohn's disease may affect any segment but commonly involves the terminal ileum. Radiation enteritis, tropical sprue, autoimmune enteropathy, and medication-induced enteropathy (olmesartan, mycophenolate) similarly impair mucosal function.

Transport phase disorders obstruct movement of absorbed nutrients from enterocytes to systemic circulation. Intestinal lymphangiectasia obstructs lymphatic drainage of chylomicrons, causing protein-losing enteropathy. Abetalipoproteinemia prevents chylomicron formation entirely due to deficient microsomal triglyceride transfer protein. Whipple disease obstructs lymphatics with PAS-positive macrophages containing Tropheryma whipplei.

The clinical features of malabsorption reflect the nutrients affected. Steatorrhea—fatty, foul-smelling, pale stools that float and are difficult to flush—indicates fat malabsorption and typically occurs when fecal fat exceeds 7 grams per day. Weight loss occurs despite adequate caloric intake. Bloating and flatulence result from bacterial fermentation of unabsorbed carbohydrates. Fat-soluble vitamin deficiencies (A, D, E, K) develop with prolonged fat malabsorption. Anemia may be microcytic (iron deficiency), macrocytic (B12 or folate deficiency), or mixed. Osteoporosis results from calcium and vitamin D malabsorption. Peripheral edema indicates protein loss or hypoalbuminemia.

The diagnostic approach begins with stool studies: qualitative fecal fat (Sudan stain), 72-hour quantitative fecal fat collection (greater than 7 g/day confirms steatorrhea), and fecal elastase (below 200 μg/g indicates pancreatic insufficiency). Blood tests include complete blood count, comprehensive metabolic panel, fat-soluble vitamins, B12, folate, iron studies, and celiac serology (tissue transglutaminase IgA with total IgA level). Imaging with CT or MR enterography identifies Crohn's disease, small bowel tumors, and structural abnormalities. Upper endoscopy with duodenal biopsies diagnoses celiac disease, Whipple disease, and other mucosal disorders. Breath tests detect lactose intolerance, fructose malabsorption, and SIBO.

<image>Panel A: Luminal phase malabsorption showing intestinal lumen with pancreatic enzyme secretion and bile acid delivery, with dysfunction markers for pancreatic insufficiency, bile acid deficiency, and SIBO. Panel B: Mucosal phase showing cross-section comparing normal tall villi with damaged blunted villi in celiac disease, including enterocyte brush border enzyme detail. Panel C: Transport phase showing enterocyte nutrient absorption with lymphatic obstruction in lymphangiectasia and chylomicron formation defects in abetalipoproteinemia. Panel D: Clinical features of malabsorption including steatorrhea, weight loss, fat-soluble vitamin deficiencies (ADEK), B12 and folate deficiency, and bone loss with diagnostic approach overview.</image>

IV. Specific Malabsorption Disorders

Pancreatic Exocrine Insufficiency (PEI) occurs when enzyme output falls below 10% of normal, as the pancreas has tremendous functional reserve. Chronic pancreatitis accounts for most cases, followed by pancreatic cancer (especially head lesions), cystic fibrosis, and post-surgical states (Whipple procedure, distal pancreatectomy). Clinical features include steatorrhea, weight loss, and fat-soluble vitamin deficiencies. Fecal elastase below 200 μg/g confirms the diagnosis (below 100 indicates severe insufficiency). Treatment centers on pancreatic enzyme replacement therapy (PERT), with lipase being the critical component since proteases and amylases have alternative sources. Initial dosing is 25,000-50,000 lipase units per meal and half that dose with snacks, taken at the start of or during meals. Adding a proton pump inhibitor improves enzyme activity by preventing acid-mediated inactivation.

Bile Acid Malabsorption (BAM) occurs when bile acids escape ileal reabsorption and enter the colon, where they stimulate secretion and motility. Type 1 BAM results from ileal disease (Crohn's) or resection. Type 2 is primary or idiopathic, characterized by overproduction. Type 3 follows cholecystectomy or accompanies other GI disorders. When mild to moderate, excess bile acids reaching the colon cause watery diarrhea. When severe, the bile acid pool becomes depleted, causing steatorrhea. Diagnosis relies on SeHCAT retention testing (not available in the US), C4 levels, or therapeutic trial of bile acid sequestrants. Treatment with cholestyramine, colesevelam, or colestipol binds bile acids and resolves symptoms.

Lactose Intolerance results from lactase deficiency at the brush border. Primary lactase deficiency represents the ancestral state, with lactase persistence being a relatively recent evolutionary adaptation; prevalence of intolerance ranges from 5% in Northern Europeans to over 90% in East Asians. Secondary lactase deficiency follows mucosal injury from celiac disease, Crohn's, infectious enteritis, or SIBO. Congenital lactase deficiency is rare and severe. Symptoms include bloating, cramping, flatulence, and osmotic diarrhea after lactose ingestion. Diagnosis uses lactose breath hydrogen testing or empiric elimination trial. Treatment involves lactose restriction and lactase enzyme supplements.

Whipple Disease, caused by Tropheryma whipplei, is a rare systemic infection affecting middle-aged men. The classic triad includes malabsorption with diarrhea and weight loss, migratory arthralgias (often preceding GI symptoms by years), and neurologic manifestations (cognitive changes, oculomasticatory myorhythmia, hypothalamic dysfunction). Fever, lymphadenopathy, and cardiac involvement also occur. Duodenal biopsy reveals PAS-positive, diastase-resistant foamy macrophages in the lamina propria. PCR for T. whipplei confirms the diagnosis. Treatment requires prolonged antibiotics: two weeks of intravenous ceftriaxone followed by one year of trimethoprim-sulfamethoxazole.

<image>Panel A: Pancreatic exocrine insufficiency showing calcified pancreas with absent enzyme secretion, fecal elastase below 200 micrograms/g diagnostic threshold, and PERT capsule with lipase units. Panel B: Bile acid malabsorption diagram of disrupted enterohepatic circulation with bile acids spilling into colon causing secretory diarrhea, and cholestyramine binding mechanism. Panel C: Lactose intolerance showing brush border lactase deficiency, undigested lactose reaching colon with bacterial fermentation producing hydrogen and CO2, osmotic water influx, and breath test diagnosis. Panel D: Whipple disease duodenal biopsy showing PAS-positive foamy macrophages in lamina propria with clinical triad of arthritis, diarrhea, and neurologic symptoms.</image>

V. Vitamin Deficiencies

Fat-soluble vitamins (A, D, E, K) require bile acids and normal fat absorption for uptake, making them particularly vulnerable in cholestatic disease, pancreatic insufficiency, and other causes of steatorrhea.

Vitamin A is essential for vision (rhodopsin synthesis), epithelial integrity, and immune function. Deficiency causes night blindness (nyctalopia) as the earliest manifestation, progressing to xerophthalmia (conjunctival and corneal drying), Bitot spots (foamy white patches on conjunctiva), and ultimately keratomalacia with corneal ulceration and blindness. Vitamin A deficiency remains a leading cause of preventable blindness globally.

Vitamin D regulates calcium and phosphorus homeostasis through intestinal absorption and renal reabsorption. Deficiency causes rickets in children (growth plate abnormalities, bowing of legs, rachitic rosary at costochondral junctions) and osteomalacia in adults (bone pain, proximal muscle weakness, pathologic fractures). Diagnosis requires 25-hydroxyvitamin D levels; below 20 ng/mL indicates deficiency. Treatment involves cholecalciferol (vitamin D3) supplementation.

Vitamin E serves as an antioxidant protecting cell membranes from lipid peroxidation. Deficiency, typically occurring after years of malabsorption, causes spinocerebellar ataxia (resembling Friedreich ataxia), peripheral neuropathy, and retinopathy. These neurologic complications reflect lipid peroxidation damage to neuronal membranes.

Vitamin K is required for gamma-carboxylation of clotting factors II, VII, IX, and X (and proteins C and S). Deficiency causes bleeding diathesis with elevated PT/INR (factor VII has the shortest half-life). Warfarin functions by inhibiting vitamin K recycling. Treatment with vitamin K reverses the coagulopathy.

Vitamin B12 (cobalamin) has a unique and complex absorption pathway. Dietary B12 is released from food proteins by gastric acid and pepsin, binds to R-protein (haptocorrin) in saliva and stomach, is released by pancreatic proteases, and then binds intrinsic factor secreted by gastric parietal cells. The B12-intrinsic factor complex travels to the terminal ileum, where cubilin receptors mediate absorption. The liver stores 3-5 years' supply, so deficiency takes years to develop after absorption ceases. Causes include pernicious anemia (autoimmune destruction of parietal cells, most common), ileal disease or resection, SIBO (bacterial consumption), and chronic PPI use (impaired release from food proteins). Deficiency causes megaloblastic anemia (hypersegmented neutrophils, macro-ovalocytes) and subacute combined degeneration of the spinal cord (dorsal column and lateral corticospinal tract demyelination causing sensory ataxia, paresthesias, and weakness). Laboratory findings include low B12, elevated methylmalonic acid (MMA), and elevated homocysteine.

Folate is absorbed in the jejunum without requiring intrinsic factor. Deficiency causes similar megaloblastic anemia but without neurologic sequelae (folate is not required for myelin synthesis). Elevated homocysteine occurs, but MMA remains normal (distinguishing from B12 deficiency). Folate deficiency during pregnancy causes neural tube defects, prompting fortification of grain products and prenatal supplementation.

Iron is absorbed as ferrous iron (Fe²⁺) in the duodenum via the divalent metal transporter 1 (DMT1). Hepcidin, the master regulator, degrades ferroportin to control iron efflux from enterocytes and macrophages. Deficiency causes microcytic, hypochromic anemia with classic laboratory findings: low ferritin, low serum iron, elevated total iron-binding capacity (TIBC), and low transferrin saturation. Clinical features include fatigue, pallor, pica (craving non-food substances), and koilonychia (spoon-shaped nails). Causes include blood loss (most common), celiac disease, H. pylori infection (affects acid and ascorbate), and gastric surgery.

<image>Panel A: Fat-soluble vitamin deficiencies showing vitamin A progression (night blindness to keratomalacia), vitamin D (rickets in children, osteomalacia in adults), vitamin E (spinocerebellar ataxia), and vitamin K (coagulopathy with elevated PT/INR). Panel B: Vitamin B12 absorption pathway from stomach acid release through R-protein binding, pancreatic protease cleavage, intrinsic factor binding, and terminal ileum cubilin receptor absorption, with deficiency causes at each step. Panel C: B12 deficiency manifestations including megaloblastic anemia (macro-ovalocytes, hypersegmented neutrophils) and subacute combined degeneration of the spinal cord (dorsal columns and lateral corticospinal tracts), with laboratory comparison of B12 versus folate (MMA, homocysteine). Panel D: Folate deficiency (jejunal absorption, neural tube defects, no neurologic findings) and iron deficiency (DMT1 absorption, hepcidin-ferroportin regulation, koilonychia, low ferritin with elevated TIBC).</image>

VI. Mineral Deficiencies

Calcium absorption occurs primarily in the duodenum through vitamin D-dependent active transport and throughout the small intestine via passive diffusion. Deficiency results from vitamin D deficiency, malabsorption, chronic kidney disease (impaired vitamin D activation), or hypoparathyroidism. Clinical features reflect neuromuscular irritability: perioral paresthesias, muscle cramps, tetany, and seizures. Chvostek's sign (facial twitching when tapping the facial nerve anterior to the ear) and Trousseau's sign (carpal spasm when blood pressure cuff inflates above systolic for three minutes) indicate latent tetany. Chronic hypocalcemia causes osteoporosis. Treatment addresses the underlying cause while providing calcium and vitamin D supplementation.

Magnesium is absorbed throughout the small intestine, with the kidney serving as the primary regulator. Deficiency results from chronic diarrhea, alcoholism (poor intake plus renal wasting), proton pump inhibitors (chronic use), and loop or thiazide diuretics. Clinical features overlap with hypocalcemia (tetany, seizures) because magnesium deficiency impairs PTH secretion and action. Hypomagnesemia causes refractory hypokalemia (magnesium is required for renal potassium conservation) and refractory hypocalcemia. Cardiac arrhythmias, particularly torsades de pointes, occur. Treatment requires oral or intravenous magnesium replacement.

Zinc supports immune function, wound healing, taste perception, and protein synthesis. Deficiency occurs with malabsorption, alcoholism, and prolonged parenteral nutrition without supplementation. Acrodermatitis is the hallmark: erythematous, scaly, crusted lesions in acral (perioral, periorbital, perineal) and acral (hands, feet) distributions—resembling acrodermatitis enteropathica, the congenital zinc transporter deficiency. Additional features include impaired wound healing, altered taste (dysgeusia), alopecia, and immune dysfunction. Serum zinc levels are unreliable; diagnosis is often clinical with therapeutic trial. Treatment with zinc supplementation produces rapid improvement.

Copper is essential for ceruloplasmin synthesis, iron metabolism, and nervous system function. Deficiency occurs with prolonged parenteral nutrition without copper supplementation, excess zinc intake (which induces metallothionein that binds copper), and gastric bypass surgery. Hematologic manifestations include anemia (often sideroblastic, with ringed sideroblasts on bone marrow) and neutropenia. Neurologic manifestations include myelopathy resembling B12 deficiency (subacute combined degeneration), with sensory ataxia and spasticity. Diagnosis shows low serum copper and ceruloplasmin. Treatment with copper supplementation reverses hematologic abnormalities; neurologic deficits may persist.

<image>Panel A: Calcium deficiency showing vitamin D-dependent duodenal absorption, Chvostek's sign (facial twitching), Trousseau's sign (carpal spasm), and osteoporosis on DEXA scan. Panel B: Magnesium deficiency with renal reabsorption diagram, causes (diarrhea, alcoholism, PPIs, diuretics), torsades de pointes on EKG, and refractory hypokalemia and hypocalcemia. Panel C: Zinc deficiency showing perioral and acral acrodermatitis with erythematous scaly lesions, impaired wound healing, dysgeusia, and immune dysfunction. Panel D: Copper deficiency with ringed sideroblasts on bone marrow, anemia and neutropenia on blood smear, and myelopathy resembling B12 deficiency (subacute combined degeneration).</image>

VII. Enteral Nutrition

When patients cannot meet nutritional needs through oral intake but have functional gastrointestinal tracts, enteral nutrition provides superior outcomes compared to parenteral nutrition. The guiding principle remains: "If the gut works, use it." Enteral feeding maintains gut barrier function, prevents bacterial translocation, stimulates gut hormones, is less expensive, and carries fewer infectious complications.

Indications include inadequate oral intake from anorexia, mechanical swallowing dysfunction (stroke, head and neck cancer), neurologic disorders (advanced dementia, motor neuron disease), critical illness with prolonged ICU stay, and some patients with short bowel syndrome during intestinal adaptation.

Access routes vary by anticipated duration and aspiration risk. Nasogastric tubes suffice for short-term feeding (less than four weeks) and can be placed at bedside with radiographic confirmation. Nasoduodenal or nasojejunal tubes bypass the stomach for patients at high aspiration risk but require fluoroscopic or endoscopic placement for reliable positioning. Percutaneous endoscopic gastrostomy (PEG) is the preferred long-term access, placed endoscopically as an outpatient procedure with low complication rates. Percutaneous endoscopic jejunostomy (PEJ) or jejunal extension through PEG (PEG-J) provides post-pyloric access for long-term use in patients with gastroparesis or aspiration risk. Surgical gastrostomy or jejunostomy is reserved for patients without endoscopic access.

Formula selection depends on digestive capacity. Polymeric formulas contain intact protein, complex carbohydrates, and long-chain triglycerides, requiring normal digestion—these are standard formulas for most patients. Semi-elemental formulas contain peptides (hydrolyzed protein) and medium-chain triglycerides (MCTs), requiring less pancreatic function and suitable for malabsorption. Elemental formulas contain free amino acids, simple sugars, and minimal fat, requiring essentially no digestion and reserved for severe malabsorption or pancreatitis. Disease-specific formulas exist for diabetes (low glycemic index, fiber), renal failure (low potassium, phosphorus), hepatic failure (branched-chain amino acids), and pulmonary disease (higher fat, lower carbohydrate to reduce CO₂ production).

Complications require prevention and management. Aspiration pneumonia, the most feared complication, is reduced by elevating the head of bed to 30-45 degrees, using post-pyloric feeding in high-risk patients, and checking gastric residual volumes (though the threshold for holding feeds is debated). Diarrhea affects up to 30% of tube-fed patients; management includes slowing infusion rate, adding fiber, ruling out Clostridioides difficile infection, and avoiding sorbitol-containing medications. Tube clogging is prevented by regular flushing and using liquid medication formulations. Refeeding syndrome requires recognition of high-risk patients and careful feeding initiation. Metabolic complications including hyperglycemia and electrolyte abnormalities require monitoring.

<image>Panel A: Feeding access routes showing nasogastric tube (short-term, under 4 weeks), nasoduodenal/nasojejunal tube (aspiration risk), PEG tube (long-term), and PEG-J with jejunal extension, each labeled with placement method and duration. Panel B: Formula types including polymeric (intact macronutrients), semi-elemental (peptides plus MCT), elemental (amino acids, simple sugars), and disease-specific formulas (diabetes, renal, hepatic). Panel C: Complication prevention with head of bed elevation to 30-45 degrees, gastric residual volume checks, regular tube flushing, and monitoring for aspiration and diarrhea. Panel D: Indications for enteral nutrition including inadequate oral intake, swallowing dysfunction, neurologic disorders, critical illness, and short bowel syndrome during adaptation.</image>

VIII. Parenteral Nutrition

When the gastrointestinal tract is nonfunctional or inaccessible, parenteral nutrition (PN) provides complete nutrition intravenously. Though life-saving in appropriate circumstances, parenteral nutrition carries significant risks and should be discontinued as soon as enteral feeding becomes feasible.

Indications for parenteral nutrition include intestinal failure states where the gut cannot absorb adequate nutrition: complete small bowel obstruction, high-output enterocutaneous fistula, severe ileus, short bowel syndrome with insufficient bowel length, severe acute pancreatitis with complications precluding enteral access, massive small bowel resection, and severe mucositis from bone marrow transplantation or chemotherapy. The anticipated duration influences access selection: peripheral PN for less than two weeks, central PN for longer duration or when higher osmolarity is required.

Components of parenteral nutrition include macronutrients and micronutrients in a sterile solution. Dextrose provides carbohydrate calories (3.4 kcal/g), typically 150-300 grams daily. The maximum oxidation rate is approximately 4-5 mg/kg/min; exceeding this causes hyperglycemia and hepatic steatosis. Amino acids provide protein, typically 1-2 g/kg/day, adjusted for renal and hepatic function. Lipid emulsions provide essential fatty acids and concentrated calories (9 kcal/g), typically 1-1.5 g/kg/day with a minimum of 2-3 infusions weekly to prevent essential fatty acid deficiency. Modern lipid emulsions include soybean oil-based (traditionally), fish oil-based (anti-inflammatory, may reduce IFALD), or mixed (SMOF—soy, MCT, olive, fish). Electrolytes (sodium, potassium, calcium, magnesium, phosphate) are added based on daily needs and laboratory monitoring. Vitamins are provided as daily multivitamin infusion. Trace elements (zinc, copper, manganese, chromium, selenium) are essential additives.

Access for peripheral PN requires osmolarity below 900 mOsm/L (approximately 10% dextrose maximum) due to venous sclerosis risk; this limits caloric delivery. Central access via PICC line, tunneled catheter (Hickman, Broviac), or implanted port allows high osmolarity solutions for full nutritional support. Selection depends on duration: PICC for weeks to months, tunneled catheter or port for months to years.

Complications fall into several categories. Catheter-related complications include infection (line sepsis is the most common serious complication), thrombosis, pneumothorax during insertion, and catheter occlusion. Strict aseptic technique and dedicated PN lines reduce infection. Metabolic complications include hyperglycemia (common, requiring insulin), hypoglycemia (if PN stopped abruptly), electrolyte abnormalities (particularly hypophosphatemia and hypokalemia), and hypertriglyceridemia. Hepatobiliary complications include steatosis, cholestasis, and intestinal failure-associated liver disease (IFALD)—a progressive cholestatic injury occurring with long-term PN, particularly in patients without enteral feeding. Strategies to prevent IFALD include cycling PN (nocturnal infusion with daytime breaks), reducing soybean lipid dose, using fish oil-based lipids, maintaining some enteral intake if possible, and treating SIBO. Bone disease (metabolic bone disease, osteoporosis) results from aluminum contamination, vitamin D abnormalities, and other factors. Essential fatty acid deficiency occurs if lipids are held or provided inadequately.

<image>Panel A: TPN bag components showing dextrose (3.4 kcal/g), amino acids (1-2 g/kg/day), lipid emulsion (9 kcal/g), electrolytes, vitamins, and trace elements with caloric density labels. Panel B: Central venous access options including PICC line, tunneled catheter (Hickman), and implanted port with duration and osmolarity tolerance for each. Panel C: Catheter and metabolic complications showing line sepsis, thrombosis, hyperglycemia, hypoglycemia, and electrolyte abnormalities. Panel D: Hepatobiliary complications with steatosis and cholestasis progressing to IFALD, prevention strategies (cycling PN, fish oil lipids, maintaining enteral feeds), and bone disease from long-term parenteral nutrition.</image>

IX. Obesity and Metabolic Consequences

Obesity has reached epidemic proportions, affecting approximately 40% of US adults with frank obesity (BMI ≥30) and an additional 30% classified as overweight. This chronic, relapsing condition results from complex interactions between genetics, environment, behavior, and increasingly recognized neuroendocrine regulation of energy balance.

The metabolic consequences of obesity extend across virtually every organ system. Metabolic syndrome—the clustering of central obesity, hypertension, dyslipidemia, and insulin resistance—dramatically increases cardiovascular risk. Cardiovascular disease includes hypertension, coronary artery disease, heart failure (both preserved and reduced ejection fraction), and stroke. Type 2 diabetes results from insulin resistance and eventual beta cell failure. Dyslipidemia features elevated triglycerides, low HDL, and small dense LDL particles. NAFLD/MASLD affects over 30% of obese individuals, with a subset progressing to steatohepatitis, cirrhosis, and hepatocellular carcinoma. Respiratory complications include obstructive sleep apnea and obesity hypoventilation syndrome (Pickwickian syndrome). Musculoskeletal effects include osteoarthritis, particularly weight-bearing joints. Cancer risk increases substantially for colorectal, breast (postmenopausal), endometrial, esophageal (adenocarcinoma), pancreatic, and kidney cancers.

Medical management begins with lifestyle intervention. Diet modifications emphasizing caloric deficit, regardless of specific macronutrient composition, produce weight loss. Physical activity of 150+ minutes weekly moderate-intensity exercise supports weight loss maintenance. Behavioral therapy, particularly cognitive behavioral therapy, addresses psychological aspects. Even 5-10% body weight loss produces clinically meaningful improvements in blood pressure, glycemic control, and lipid profiles.

Pharmacotherapy has advanced significantly. GLP-1 receptor agonists (semaglutide, liraglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce substantial weight loss (15-20% with high-dose tirzepatide) through central appetite suppression and delayed gastric emptying, with additional cardiovascular and metabolic benefits. Side effects include nausea, vomiting, and rare pancreatitis risk. Orlistat inhibits pancreatic lipase, reducing fat absorption by 30%, but causes steatorrhea and is limited by tolerability. Older agents (phentermine, phentermine-topiramate, naltrexone-bupropion) remain options but with less impressive efficacy.

Bariatric surgery offers the most effective and durable weight loss for severe obesity. Indications include BMI ≥40 or BMI ≥35 with obesity-related comorbidities. Sleeve gastrectomy, now the most commonly performed procedure, involves removing approximately 80% of the stomach to create a tubular pouch—primarily restrictive but also reduces ghrelin production. Roux-en-Y gastric bypass creates a small gastric pouch anastomosed to a Roux limb of jejunum, bypassing most of the stomach and duodenum—combining restriction with malabsorption and significant hormonal changes. Adjustable gastric band use has declined due to complications and inferior long-term outcomes. Biliopancreatic diversion with duodenal switch produces maximum weight loss through significant malabsorption but carries highest nutritional deficiency risk. Outcomes include 20-35% total body weight loss sustained long-term, high rates of diabetes remission (particularly with bypass), improvement or resolution of hypertension and sleep apnea, and reduced mortality. Complications include dumping syndrome (particularly with bypass), marginal ulcers, internal hernias, nutritional deficiencies (iron, B12, calcium, fat-soluble vitamins), and need for lifelong monitoring and supplementation.

<image>Panel A: Metabolic syndrome components with visceral adiposity connected to cardiovascular disease, stroke, NAFLD spectrum, obstructive sleep apnea, osteoarthritis, and cancer risk, with laboratory abnormalities (elevated glucose, triglycerides, BP, low HDL). Panel B: Pharmacotherapy showing GLP-1 agonist mechanism (appetite suppression, delayed gastric emptying, insulin secretion) and weight loss efficacy comparison (lifestyle 5%, orlistat 10%, GLP-1 15%, tirzepatide 20%). Panel C: Bariatric surgery procedures showing sleeve gastrectomy (vertical stomach tube), Roux-en-Y gastric bypass (small pouch with Roux limb), and adjustable gastric band with expected weight loss percentages. Panel D: Bariatric surgery indications (BMI 40 or above, or BMI 35 or above with comorbidities), outcomes including diabetes remission and mortality reduction, and complications including dumping syndrome, nutritional deficiencies, and lifelong monitoring requirements.</image>

X. Refeeding Syndrome

Refeeding syndrome is a potentially fatal shift in fluids and electrolytes that occurs when malnourished patients receive nutritional repletion, whether enteral or parenteral. Understanding the pathophysiology enables recognition of high-risk patients and implementation of preventive strategies.

Pathophysiology begins during starvation. Without carbohydrate intake, insulin secretion falls, and the body shifts to fat and protein catabolism for energy. Gluconeogenesis and ketogenesis become primary metabolic pathways. Intracellular stores of phosphorus, potassium, and magnesium become depleted as these minerals are lost through catabolism, but serum levels may remain normal as intracellular contents shift to maintain plasma concentrations. Thiamine stores become depleted as a cofactor for carbohydrate metabolism is not utilized.

When refeeding begins, particularly with carbohydrate-rich nutrition, insulin secretion surges. Insulin drives glucose into cells for glycolysis and glycogen synthesis. Critically, insulin also drives potassium, phosphorus, and magnesium into cells along with glucose. The already depleted intracellular stores plus this acute intracellular shift causes precipitous drops in serum levels. Additionally, carbohydrate metabolism suddenly increases demand for thiamine as a cofactor for pyruvate dehydrogenase, transketolase, and alpha-ketoglutarate dehydrogenase.

Hypophosphatemia is the hallmark of refeeding syndrome. Phosphorus is essential for ATP synthesis (the cellular energy currency), 2,3-DPG (oxygen delivery from hemoglobin), membrane phospholipids, and nucleic acids. Severe hypophosphatemia causes respiratory failure (diaphragm weakness), cardiac failure, rhabdomyolysis, hemolysis (decreased 2,3-DPG and membrane instability), seizures, and death.

Hypokalemia causes cardiac arrhythmias, muscle weakness, and ileus. Hypomagnesemia causes arrhythmias, seizures, and exacerbates hypokalemia and hypocalcemia. Thiamine deficiency causes Wernicke encephalopathy (ataxia, ophthalmoplegia, confusion) and Korsakoff syndrome; giving glucose without thiamine can precipitate Wernicke encephalopathy.

High-risk patients include those with BMI below 16, unintentional weight loss greater than 15% in 3-6 months, little or no nutritional intake for more than 10 days, low baseline phosphorus, potassium, or magnesium, and history of alcohol misuse, anorexia nervosa, or cancer.

Prevention and management follow a structured approach. First, identify high-risk patients using the criteria above. Second, check and correct electrolytes before initiating nutrition, particularly phosphorus, potassium, and magnesium. Third, administer thiamine (200-300 mg IV or oral) before the first feeding and continue for at least three days—this prevents carbohydrate loading from precipitating Wernicke encephalopathy. Fourth, start nutrition slowly: 10-20 kcal/kg/day (or as low as 5-10 kcal/kg/day in extreme cases), advancing by 5-10 kcal/kg/day every 1-2 days over 5-7 days. Fifth, monitor electrolytes daily (or twice daily in highest-risk patients) for at least the first week, supplementing as needed. Sixth, monitor clinically for signs of fluid overload, cardiac dysfunction, and respiratory compromise.

<image>Panel A: Starvation to refeeding timeline showing depleted intracellular stores with normal serum levels during starvation, insulin surge upon carbohydrate refeeding, and precipitous serum drops in phosphorus, potassium, and magnesium. Panel B: Consequences by electrolyte showing hypophosphatemia (ATP depletion, respiratory failure, cardiac failure, hemolysis), hypokalemia (arrhythmias, muscle weakness), hypomagnesemia (torsades de pointes, refractory hypokalemia), and thiamine deficiency (Wernicke encephalopathy). Panel C: High-risk patient identification with BMI below 16, weight loss greater than 15% in 3-6 months, no intake for more than 10 days, and history of alcohol misuse or anorexia nervosa. Panel D: Prevention protocol flowchart showing check electrolytes, give thiamine 200-300 mg before feeding, start feeds at 10-20 kcal/kg/day, advance slowly over 5-7 days, and monitor electrolytes daily.</image>

Summary

Nutritional assessment integrates history, examination, anthropometrics, laboratory markers, and functional testing; albumin and prealbumin are negative acute phase reactants limited by inflammation. Macronutrient requirements approximate 25-35 kcal/kg/day for energy, 0.8-2.0 g/kg/day for protein depending on clinical context, and essential fatty acids to prevent deficiency.

Malabsorption results from luminal (pancreatic insufficiency, bile acid deficiency), mucosal (celiac disease, Crohn's), or transport (lymphatic obstruction) phase dysfunction. Fecal elastase below 200 μg/g indicates pancreatic insufficiency treated with PERT. Bile acid malabsorption causes diarrhea responsive to sequestrants.

Vitamin deficiencies have characteristic presentations: B12 deficiency requires intrinsic factor and intact ileum, causing megaloblastic anemia and subacute combined degeneration; folate deficiency causes megaloblastic anemia without neurologic findings; fat-soluble vitamin deficiencies (ADEK) accompany steatorrhea.

Enteral nutrition follows the principle "if the gut works, use it," with access selection based on duration and aspiration risk. Parenteral nutrition is reserved for intestinal failure, carrying risks of catheter infection, metabolic complications, and IFALD.

Obesity's metabolic consequences span cardiovascular disease, diabetes, NAFLD, sleep apnea, and cancer. GLP-1 agonists and bariatric surgery produce substantial, durable weight loss.

Refeeding syndrome, precipitated by feeding malnourished patients, causes dangerous hypophosphatemia, hypokalemia, and hypomagnesemia. Prevention requires identifying high-risk patients, giving thiamine first, starting feeds slowly, and monitoring electrolytes closely.

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown